# Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri

> **NCT02137109** · — · COMPLETED · sponsor: **Biogen** · enrollment: 400 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** natalizumab

## Key facts

- **NCT ID:** NCT02137109
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2015-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02137109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02137109, "Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02137109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*